Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06304818

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours

Sponsor: Sinocelltech Ltd.

Conditions Advanced Malignant Solid Tumours

Interventions SCTB14

Updated 3 times since 2024 Last updated: Mar 13, 2024 Started: Apr 30, 2024 Primary completion: Dec 30, 2027 Completion: Dec 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Malignant Solid Tumours and is currently actively recruiting participants. Sinocelltech Ltd. leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinocelltech Ltd.

Data source: Sinocelltech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.